Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C56H87NO16 |
Molecular Weight | 1030.2871 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
InChI
InChIKey=CBPNZQVSJQDFBE-FUXHJELOSA-N
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
Molecular Formula | C56H87NO16 |
Molecular Weight | 1030.2871 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB06287Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000_PRNTLBL.pdf
Sources: http://www.drugbank.ca/drugs/DB06287
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000_PRNTLBL.pdf
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel. Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2842 Sources: http://www.drugbank.ca/drugs/DB06287 |
1.76 µM [IC50] | ||
Target ID: CHEMBL614067 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27526062 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Torisel Approved UseTreatment of advanced renal cell carcinoma (RCC) Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
585 ng/mL |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMSIROLIMUS blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1627 ng × h/mL |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMSIROLIMUS blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.3 h |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMSIROLIMUS blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11% |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMSIROLIMUS blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
150 mg/m2 1 times / week multiple, intravenous Dose: 150 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / week Sources: |
unhealthy, 11 years (range: 4-21 years) Health Status: unhealthy Age Group: 11 years (range: 4-21 years) Sex: M+F Sources: |
DLT: Anorexia... Dose limiting toxicities: Anorexia (grade 3, 1 patient) Sources: |
220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
DLT: Stomatitis, Asthenia... Other AEs: Mucositis, Mucositis... Dose limiting toxicities: Stomatitis (grade 3, 1 patient) Other AEs:Asthenia (grade 3, 1 patient) Mucositis (grade 1-2, 7 patients) Sources: Mucositis (grade 3-4, 1 patient) Nausea (grade 1-2, 5 patients) Thrombocytopenia (grade 1-2, 1 patient) Diarrhea (grade 1-2, 1 patient) Vomiting (grade 1-2, 3 patients) Hypercholesterolemia (grade 3-4, 2 patients) Hypertriglyceridemia (grade 3-4, 1 patient) Peripheral edema (grade 1-2, 2 patients) Weight loss (grade 1-2, 2 patients) Taste perversion (grade 1-2, 2 patients) |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Other AEs: Asthenia, Asthenia... Other AEs: Asthenia (all grades, 51%) Sources: Asthenia (grade 3-4, 11%) Edema (all grades, 35%) Edema face (all grades, 35%) Peripheral edema (all grades, 35%) Edema (grade 3-4, 3%) Edema face (grade 3-4, 3%) Peripheral edema (grade 3-4, 3%) Pain (all grades, 28%) Pain (grade 3-4, 5%) Pyrexia (all grades, 24%) Pyrexia (grade 3-4, 1%) Weight loss (all grades, 19%) Weight loss (grade 3-4, 1%) Headache (all grades, 15%) Headache (grade 3-4, 1%) Chest pain (all grades, 16%) Chest pain (grade 3-4, 1%) Chills (all grades, 8%) Chills (grade 3-4, 1%) Aphthous stomatitis (all grades, 41%) Glossitis (all grades, 41%) Mouth ulceration (all grades, 41%) Mucositis (all grades, 41%) Stomatitis (all grades, 41%) Aphthous stomatitis (grade 3-4, 3%) Glossitis (grade 3-4, 3%) Mouth ulceration (grade 3-4, 3%) Mucositis (grade 3-4, 3%) Stomatitis (grade 3-4, 3%) Anorexia (all grades, 32%) Anorexia (grade 3-4, 3%) Nausea (all grades, 37%) Nausea (grade 3-4, 2%) Diarrhea (all grades, 27%) Diarrhea (grade 3-4, 1%) Abdominal pain (all grades, 21%) Abdominal pain (grade 3-4, 4%) Constipation (all grades, 20%) Vomiting (all grades, 19%) Vomiting (grade 3-4, 2%) Infection NOS (all grades, 20%) Abscess (all grades, 20%) Bronchitis (all grades, 20%) Cellulitis (all grades, 20%) Herpes simplex (all grades, 20%) Herpes zoster (all grades, 20%) Infection NOS (grade 3-4, 3%) Abscess (grade 3-4, 3%) Bronchitis (grade 3-4, 3%) Cellulitis (grade 3-4, 3%) Herpes simplex (grade 3-4, 3%) Herpes zoster (grade 3-4, 3%) Cystitis (all grades, 15%) Dysuria (all grades, 15%) Hematuria (all grades, 15%) Urinary frequency (all grades, 15%) Urinary tract infection (all grades, 15%) Cystitis (grade 3-4, 1%) Dysuria (grade 3-4, 1%) Hematuria (grade 3-4, 1%) Urinary frequency (grade 3-4, 1%) Urinary tract infection (grade 3-4, 1%) Pharyngitis (all grades, 12%) Rhinitis (all grades, 10%) Back pain (all grades, 20%) Back pain (grade 3-4, 3%) Arthralgia (all grades, 18%) Arthralgia (grade 3-4, 1%) Myalgia (all grades, 8%) Myalgia (grade 3-4, 1%) Dyspnea (all grades, 28%) Dyspnea (grade 3-4, 9%) Cough (all grades, 26%) Cough (grade 3-4, 1%) Epistaxis (all grades, 12%) Eczema (all grades, 47%) Exfoliative dermatitis (all grades, 47%) Maculopapular rash (all grades, 47%) Pruritic rash (all grades, 47%) Pustular rash (all grades, 47%) Rash NOS (all grades, 47%) Vesiculobullous rash (all grades, 47%) Epistaxis (grade 3-4, 5%) Eczema (grade 3-4, 5%) Exfoliative dermatitis (grade 3-4, 5%) Maculopapular rash (grade 3-4, 5%) Pruritic rash (grade 3-4, 5%) Pustular rash (grade 3-4, 5%) Rash NOS (grade 3-4, 5%) Vesiculobullous rash (grade 3-4, 5%) Pruritus (all grades, 19%) Pruritus (grade 3-4, 1%) Nail disorder (all grades, 14%) Dry skin (all grades, 11%) Dry skin (grade 3-4, 1%) Acne (all grades, 10%) Taste loss (all grades, 20%) Taste perversion (all grades, 20%) Insomnia (all grades, 12%) Insomnia (grade 3-4, 1%) Depression (all grades, 4%) Conjunctivitis (7%) Hypersensitivity reaction (9%) Pneumonia (8%) Upper respiratory tract infection (7%) Healing impaired (1%) Hypertension (7%) Venous thromboembolism (2%) Thrombophlebitis (1%) Hemoglobin decreased (all grades, 94%) Hemoglobin decreased (grade 3-4, 20%) Lymphocyte count decreased (all grades, 53%) Lymphocyte count decreased (grade 3-4, 16%) Neutrophil count decreased (all grades, 19%) Neutrophil count decreased (grade 3-4, 5%) Platelets decreased (all grades, 40%) Platelets decreased (grade 3-4, 1%) Leukocyte count decreased (all grades, 32%) Leukocyte count decreased (grade 3-4, 1%) Alkaline phosphatase increased (all grades, 68%) Alkaline phosphatase increased (grade 3-4, 3%) AST increased (all grades, 38%) AST increased (grade 3-4, 2%) Creatinine increased (all grades, 57%) Creatinine increased (grade 3-4, 3%) Glucose increased (all grades, 89%) Glucose increased (grade 3-4, 16%) Blood phosphorus decreased (all grades, 49%) Blood phosphorus decreased (grade 3-4, 18%) Bilirubin total increased (all grades, 8%) Bilirubin total increased (grade 3-4, 1%) Cholesterol total increased (all grades, 87%) Cholesterol total increased (grade 3-4, 2%) Triglyceride increased (all grades, 83%) Triglyceride increased (grade 3-4, 44%) Potassium decreased (all grades, 21%) Potassium decreased (grade 3-4, 5%) |
10 mg/m2 3 times / week multiple, intravenous Dose: 10 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 10 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
DLT: Hypertension, Mucositis... Dose limiting toxicities: Hypertension (grade 3, 1 patient) Sources: Mucositis (grade 3, 1 patient) Gamma-glutamyltransferase increased (grade 3, 1 patient) Hypertriglyceridaemia (grade 4, 1 patient) |
7.5 mg/m2 2 times / week multiple, intravenous Dose: 7.5 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 2 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
DLT: Hypertriglyceridemia, Gamma-glutamyltransferase increased... Dose limiting toxicities: Hypertriglyceridemia (grade 4, 2 patients) Sources: Gamma-glutamyltransferase increased (1 patient) Alkaline phosphatase increased (1 patient) Anorexia (grade 2, 1 patient) |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
DLT: Sepsis, Mucositis... Dose limiting toxicities: Sepsis (grade 5, 1 patient) Sources: Mucositis (grade 5, 1 patient) Acidosis (grade 5, 1 patient) Reversible posterior leukoencephalopathy syndrome (1 patient) Perianal ulcer (grade 2, 1 patient) Gamma-glutamyltransferase increased (1 patient) |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Interstitial lung disease, Asthenia... AEs leading to discontinuation/dose reduction: Interstitial lung disease (grade 5) Sources: Asthenia (3 patients) Creatinine increased (3 patients) Anemia (2 patients) Abdominal pain (2 patients) Peripheral edema (2 patients) Cerebrovascular accident (grade 5, 1 patient) Dyspnea (1 patient) Lung infiltration (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anorexia | grade 3, 1 patient DLT |
150 mg/m2 1 times / week multiple, intravenous Dose: 150 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / week Sources: |
unhealthy, 11 years (range: 4-21 years) Health Status: unhealthy Age Group: 11 years (range: 4-21 years) Sex: M+F Sources: |
Diarrhea | grade 1-2, 1 patient | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Thrombocytopenia | grade 1-2, 1 patient | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Peripheral edema | grade 1-2, 2 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Taste perversion | grade 1-2, 2 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Weight loss | grade 1-2, 2 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Vomiting | grade 1-2, 3 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Nausea | grade 1-2, 5 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Mucositis | grade 1-2, 7 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Asthenia | grade 3, 1 patient DLT |
220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Stomatitis | grade 3, 1 patient DLT |
220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Hypertriglyceridemia | grade 3-4, 1 patient | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Mucositis | grade 3-4, 1 patient | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Hypercholesterolemia | grade 3-4, 2 patients | 220 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 220 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 220 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 30-63 years) Health Status: unhealthy Age Group: 54 years (range: 30-63 years) Sex: M+F Sources: |
Healing impaired | 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Thrombophlebitis | 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Venous thromboembolism | 2% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Conjunctivitis | 7% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Hypertension | 7% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Upper respiratory tract infection | 7% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pneumonia | 8% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Hypersensitivity reaction | 9% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Acne | all grades, 10% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Rhinitis | all grades, 10% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Dry skin | all grades, 11% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Epistaxis | all grades, 12% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Insomnia | all grades, 12% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pharyngitis | all grades, 12% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Nail disorder | all grades, 14% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cystitis | all grades, 15% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Dysuria | all grades, 15% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Headache | all grades, 15% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Hematuria | all grades, 15% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Urinary frequency | all grades, 15% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Urinary tract infection | all grades, 15% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Chest pain | all grades, 16% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Arthralgia | all grades, 18% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Neutrophil count decreased | all grades, 19% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pruritus | all grades, 19% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Vomiting | all grades, 19% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Weight loss | all grades, 19% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Abscess | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Back pain | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Bronchitis | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cellulitis | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Constipation | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Herpes simplex | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Herpes zoster | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Infection NOS | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Taste loss | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Taste perversion | all grades, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Abdominal pain | all grades, 21% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Potassium decreased | all grades, 21% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pyrexia | all grades, 24% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cough | all grades, 26% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Diarrhea | all grades, 27% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Dyspnea | all grades, 28% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pain | all grades, 28% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Anorexia | all grades, 32% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Leukocyte count decreased | all grades, 32% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Edema face | all grades, 35% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Edema | all grades, 35% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Peripheral edema | all grades, 35% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Nausea | all grades, 37% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
AST increased | all grades, 38% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Depression | all grades, 4% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Platelets decreased | all grades, 40% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Aphthous stomatitis | all grades, 41% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Glossitis | all grades, 41% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Mouth ulceration | all grades, 41% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Mucositis | all grades, 41% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Stomatitis | all grades, 41% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Eczema | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Exfoliative dermatitis | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Maculopapular rash | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pruritic rash | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pustular rash | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Rash NOS | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Vesiculobullous rash | all grades, 47% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Blood phosphorus decreased | all grades, 49% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Asthenia | all grades, 51% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Lymphocyte count decreased | all grades, 53% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Creatinine increased | all grades, 57% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Alkaline phosphatase increased | all grades, 68% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Bilirubin total increased | all grades, 8% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Chills | all grades, 8% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Myalgia | all grades, 8% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Triglyceride increased | all grades, 83% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cholesterol total increased | all grades, 87% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Glucose increased | all grades, 89% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Hemoglobin decreased | all grades, 94% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Arthralgia | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Bilirubin total increased | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Chest pain | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Chills | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cough | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cystitis | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Diarrhea | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Dry skin | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Dysuria | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Headache | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Hematuria | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Insomnia | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Leukocyte count decreased | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Myalgia | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Platelets decreased | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pruritus | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pyrexia | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Urinary frequency | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Urinary tract infection | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Weight loss | grade 3-4, 1% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Asthenia | grade 3-4, 11% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Glucose increased | grade 3-4, 16% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Lymphocyte count decreased | grade 3-4, 16% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Blood phosphorus decreased | grade 3-4, 18% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
AST increased | grade 3-4, 2% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cholesterol total increased | grade 3-4, 2% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Nausea | grade 3-4, 2% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Vomiting | grade 3-4, 2% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Hemoglobin decreased | grade 3-4, 20% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Abscess | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Alkaline phosphatase increased | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Anorexia | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Aphthous stomatitis | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Back pain | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Bronchitis | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Cellulitis | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Creatinine increased | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Edema face | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Edema | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Glossitis | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Herpes simplex | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Herpes zoster | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Infection NOS | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Mouth ulceration | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Mucositis | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Peripheral edema | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Stomatitis | grade 3-4, 3% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Abdominal pain | grade 3-4, 4% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Triglyceride increased | grade 3-4, 44% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Eczema | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Epistaxis | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Exfoliative dermatitis | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Maculopapular rash | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Neutrophil count decreased | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pain | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Potassium decreased | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pruritic rash | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Pustular rash | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Rash NOS | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Vesiculobullous rash | grade 3-4, 5% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Dyspnea | grade 3-4, 9% | 25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy, 59 years (range 23-86) Health Status: unhealthy Age Group: 59 years (range 23-86) Sex: M+F Sources: |
Gamma-glutamyltransferase increased | grade 3, 1 patient DLT |
10 mg/m2 3 times / week multiple, intravenous Dose: 10 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 10 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Hypertension | grade 3, 1 patient DLT |
10 mg/m2 3 times / week multiple, intravenous Dose: 10 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 10 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Mucositis | grade 3, 1 patient DLT |
10 mg/m2 3 times / week multiple, intravenous Dose: 10 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 10 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Hypertriglyceridaemia | grade 4, 1 patient DLT |
10 mg/m2 3 times / week multiple, intravenous Dose: 10 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 10 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Alkaline phosphatase increased | 1 patient DLT |
7.5 mg/m2 2 times / week multiple, intravenous Dose: 7.5 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 2 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Gamma-glutamyltransferase increased | 1 patient DLT |
7.5 mg/m2 2 times / week multiple, intravenous Dose: 7.5 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 2 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Anorexia | grade 2, 1 patient DLT |
7.5 mg/m2 2 times / week multiple, intravenous Dose: 7.5 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 2 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Hypertriglyceridemia | grade 4, 2 patients DLT |
7.5 mg/m2 2 times / week multiple, intravenous Dose: 7.5 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 2 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Gamma-glutamyltransferase increased | 1 patient DLT |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Reversible posterior leukoencephalopathy syndrome | 1 patient DLT |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Perianal ulcer | grade 2, 1 patient DLT |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Acidosis | grade 5, 1 patient DLT |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Mucositis | grade 5, 1 patient DLT |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Sepsis | grade 5, 1 patient DLT |
7.5 mg/m2 3 times / week multiple, intravenous Dose: 7.5 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 7.5 mg/m2, 3 times / week Sources: |
unhealthy, 9 years (range: 1-21 years) Health Status: unhealthy Age Group: 9 years (range: 1-21 years) Sex: M+F Sources: |
Dyspnea | 1 patient Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Lung infiltration | 1 patient Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Abdominal pain | 2 patients Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Anemia | 2 patients Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Peripheral edema | 2 patients Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Asthenia | 3 patients Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Creatinine increased | 3 patients Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Cerebrovascular accident | grade 5, 1 patient Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Interstitial lung disease | grade 5 Disc. AE |
25 mg 1 times / week steady, intravenous Recommended Dose: 25 mg, 1 times / week Route: intravenous Route: steady Dose: 25 mg, 1 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.pfizer.ca/sites/default/files/201710/TORISEL_PM_199380_21Dec2016_E.pdf#page=34 Page: 34.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. | 2015 Jul |
|
Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. | 2017 Feb |
Patents
Sample Use Guides
Renal Cell Carcinoma
General Dosage
IV
25 mg once weekly.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27526062
Temsirolimus (10uM) inhibited the growth of Human Renal Cell Carcinoma Caki-1 growth approx. by 60%
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:50 GMT 2025
by
admin
on
Mon Mar 31 18:09:50 GMT 2025
|
Record UNII |
624KN6GM2T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175076
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
TORISEL (AUTHORIZED: LYMPHOMA, MANTLE-CELL)
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
TORISEL (AUTHORIZED: CARCINOMA, RENAL CELL)
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
NDF-RT |
N0000175605
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
NCI_THESAURUS |
C2201
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
196404
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
LIVERTOX |
NBK548811
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
WHO-ATC |
L01XE09
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
WHO-VATC |
QL01XE09
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/06/365
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB21308
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
LL-109
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
5892
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
7931
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
DB06287
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
4161
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
Temsirolimus
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
8212
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
m10555
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
624KN6GM2T
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
C401859
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
6918289
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
Temsirolimus
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201182
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
162635-04-3
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
DTXSID2040945
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
C1844
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
100000089582
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | |||
|
657797
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY | RxNorm | ||
|
624KN6GM2T
Created by
admin on Mon Mar 31 18:09:50 GMT 2025 , Edited by admin on Mon Mar 31 18:09:50 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
BINDER->LIGAND |
The percentage of [14C]temsirolimus bound to proteins at concentrations of 100 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 87.1%.
BINDING
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TARGET -> INHIBITOR |
|
||
|
BINDER->LIGAND |
The percentage of [14C]temsirolimus bound to proteins at concentrations of 10 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 85.0%
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||